{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T07:16:06Z","timestamp":1750835766588,"version":"3.40.5"},"reference-count":129,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The idea of using the lytic power of viruses against malignant cells has been entertained\nfor many decades. However, oncolytic viruses gained broad attention as an emerging anti-cancer\ntherapy only recently with the successful implementation of several oncolytic viruses to treat advanced\nmelanoma. Here we review the history of oncolytic viruses in the Russian Federation and\nrecent biotechnological advances in connection with the perspectives of their practical use against\naggressive tumors such as glioblastoma or pancreatic cancer. A particular emphasis is made on novel\napplications of safe non-lytic virus-derived vectors armed with prodrug-converting enzyme\ntransgenes. Rational improvement of oncotropism by conjugation with biopolymers and nanoformulations\nis also discussed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201023666220516121813","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T07:55:20Z","timestamp":1652774120000},"page":"266-278","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anti-cancer Virotherapy in Russia: Lessons from the Past, Current\nChallenges and Prospects for the Future"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-0120","authenticated-orcid":true,"given":"Nikolay B.","family":"Pestov","sequence":"first","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian\nAcademy of Sciences, Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Poselok Instituta Poliomielita\n8 bd 17, Poselenie Moskovskiy, Moscow, 108819, Russia"},{"name":"Moscow Institute of Physics and Technology, Phystech\nSchool of Biological and Medical Physics, Laboratory of Molecular Oncology, 9 Institutskiy per., Dolgoprudny,\nMoscow Region, 141701, Russia"},{"name":"Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Group of Cross-Linking\nEnzymes, Miklukho-Maklaya 16\/10, Moscow, 117997, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9934-2582","authenticated-orcid":true,"given":"Nadezhda M.","family":"Kolyasnikova","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian\nAcademy of Sciences, Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Poselok Instituta Poliomielita\n8 bd 17, Poselenie Moskovskiy, Moscow, 108819, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne P.","family":"Sanchez-Pimentel","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian\nAcademy of Sciences, Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Poselok Instituta Poliomielita\n8 bd 17, Poselenie Moskovskiy, Moscow, 108819, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7111-2446","authenticated-orcid":true,"given":"Nikolay A.","family":"Barlev","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian\nAcademy of Sciences, Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Poselok Instituta Poliomielita\n8 bd 17, Poselenie Moskovskiy, Moscow, 108819, Russia"},{"name":"Moscow Institute of Physics and Technology, Phystech\nSchool of Biological and Medical Physics, Laboratory of Molecular Oncology, 9 Institutskiy per., Dolgoprudny,\nMoscow Region, 141701, Russia"},{"name":"Institute of Biomedical Chemistry, Pogodinskaya 10,\nMoscow, 119435, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-4145","authenticated-orcid":true,"given":"Aidar A.","family":"Ishmukhametov","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian\nAcademy of Sciences, Laboratory of Tick-Borne Encephalitis and Other Viral Encephalitides, Poselok Instituta Poliomielita\n8 bd 17, Poselenie Moskovskiy, Moscow, 108819, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejphar.2018.08.042","volume":"837","author":"Alberts P.","year":"2018","unstructured":"Alberts P.; Tilgase A.; Rasa A.; Bandere K.; Venskus D.; The advent of oncolytic virotherapy in oncology: The Rigvir&#xAE; story. Eur J Pharmacol 2018,837,117-126","journal-title":"Eur J Pharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/1568009618666171129221503","volume":"18","author":"Liang M.","year":"2018","unstructured":"Liang M.; Oncorine, the World First Oncolytic virus medicine and its update in China. Curr Cancer Drug Targets 2018,18(2),171-176","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaad.2020.01.039","volume":"83","author":"Haitz K.","year":"2020","unstructured":"Haitz K.; Khosravi H.; Lin J.Y.; Menge T.; Nambudiri V.E.; Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. J Am Acad Dermatol 2020,83(1),189-196","journal-title":"J Am Acad Dermatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/v13081420","volume":"13","author":"Nettelbeck D.M.","year":"2021","unstructured":"Nettelbeck D.M.; Leber M.F.; Altomonte J.; Angelova A.; Beil J.; Berchtold S.; Delic M.; Eberle J.; Ehrhardt A.; Engeland C.E.; Fechner H.; Geletneky K.; Goepfert K.; Holm P.S.; Kochanek S.; Kreppel F.; Krutzke L.; K&#xFC;hnel F.; Lang K.S.; Marchini A.; Moehler M.; M&#xFC;hlebach M.D.; Naumann U.; Nawroth R.; N&#xFC;esch J.; Rommelaere J.; Lauer U.M.; Ungerechts G.; Virotherapy in Germany-recent activities in virus engineering, preclinical development, and clinical studies. Viruses 2021,13(8),1420","journal-title":"Viruses"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.mt.6300108","volume":"15","author":"Kelly E.","year":"2007","unstructured":"Kelly E.; Russell S.J.; History of oncolytic viruses: Genesis to genetic engineering. Mol Ther 2007,15(4),651-659","journal-title":"Mol Ther"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/00000441-190412740-00001","volume":"127","author":"Dock G.","year":"1904","unstructured":"Dock G.; The influence of complicating diseases upon leuk&#xE6;mia. Am J Med Sci 1904,127(4),563-592","journal-title":"Am J Med Sci"},{"key":"ref=7","first-page":"82","volume":"9","author":"de Pace N.G.","year":"1912","unstructured":"de Pace N.G.; Sulla Scomparsa di un enorme cancro vegetante del collo dell utero senza cura chirurgica. Ginecologia 1912,9,82-88","journal-title":"Ginecologia"},{"key":"ref=8","first-page":"347","author":"Shen R.M.","year":"1949","unstructured":"Shen R.M.;  Problems of Medical Virology 1949,347","journal-title":"Problems of Medical Virology"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/1097-0142(194905)2:3<525:::AID-CNCR2820020317>3.0.CO;2-O","volume":"2","author":"Moore A.E.","year":"1949","unstructured":"Moore A.E.; The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer 1949,2(3),525-534","journal-title":"Cancer"},{"key":"ref=10","first-page":"30","volume":"5","author":"Levkovich E.N.","year":"1960","unstructured":"Levkovich E.N.; Karpovich L.G.; A comparative study on viruses of the tick-borne encephalytis group in cultures of HeLa cells. Vopr Virusol 1960,5(1),30-39","journal-title":"Vopr Virusol"},{"key":"ref=11","author":"Sergeeva G.I.","year":"1966","unstructured":"Sergeeva G.I.; Levkovich E.N.; Studies on reproduction properties of certain viruses from the tick-borne encephalytis complex with different degrees of neurovirulence in tumor cells in vitro and in vivo. Voprosy Virusologii 1966","journal-title":"Voprosy Virusologii"},{"key":"ref=12","first-page":"88","author":"Levkovich E.N.","year":"1966","unstructured":"Levkovich E.N.; Sergeeva G.I.; Inhibitory action of viruses from the tick-borne encephalytis complex with different degrees of neurovirulence on murine tumors in vivo. Vopr Virusol 1966,88-91","journal-title":"Vopr Virusol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/1097-0142(197610)38:4<1796::AID-CNCR2820380457>3.0.CO;2-Y","volume":"38","author":"Tsypkin L.B.","year":"1976","unstructured":"Tsypkin L.B.; Voroshilova M.K.; Goryunova A.G.; Lavrova I.K.; Koroleva G.A.; The morphology of tumors of the human gastrointestinal tract in short-term organ culture and the reaction of these tumors to infection with poliovirus. Cancer 1976,38(4),1796-1806","journal-title":"Cancer"},{"key":"ref=14","first-page":"17","author":"Voroshilova M.K.","year":"1977","unstructured":"Voroshilova M.K.; Goryuniva A.G.; Gorbachkov E.A.; Chumakov P.M.; Oganian T.G.; Kodkind G.H.;  Studies on cellular immunity of oncology patients in the process of asymptomic enteroviral infection 1977,17-20","journal-title":"Studies on cellular immunity of oncology patients in the process of asymptomic enteroviral infection"},{"key":"ref=15","author":"Voroshilova M.K.","year":"1969","unstructured":"Voroshilova M.K.; Vaganova N.T.;  Treatment of patients with gastro-intestinal tract tumors with live enteroviral vaccines 1969","journal-title":"Treatment of patients with gastro-intestinal tract tumors with live enteroviral vaccines"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e0195425","DOI":"10.1371\/journal.pone.0195425","volume":"13","author":"Yurchenko K.S.","year":"2018","unstructured":"Yurchenko K.S.; Zhou P.; Kovner A.V.; Zavjalov E.L.; Shestopalova L.V.; Shestopalov A.M.; Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. PLoS One 2018,13(4),e0195425","journal-title":"PLoS One"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.17650\/1818-8346-2019-14-4-84-89","volume":"14","author":"Babaeva F.E.","year":"2019","unstructured":"Babaeva F.E.; Lipatova A.V.; Kochetkov D.V.; Chumakov P.M.; Kravchenko S.K.; The study of oncolytic viruses reproduction in organ cultures of human lymphoid tumors. Oncohematology 2019,14(4),84-89","journal-title":"Oncohematology"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.15690\/vramn.v68i12.853","volume":"68","author":"Razumov I.A.","year":"2013","unstructured":"Razumov I.A.; Sviatchenko V.A.; Protopopova E.V.; Kochneva G.V.; Kiselev N.N.; Gubanova N.V.; Shilov A.G.; Mordvinov V.A.; Netesov S.V.; Chumakov P.M.; Loktev V.B.; Oncolytic properties of some orthopoxviruses, adenoviruses and parvoviruses in human glioma cells. Vestn Ross Akad Med Nauk 2013,68(12),4-8","journal-title":"Vestn Ross Akad Med Nauk"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"E173","DOI":"10.3390\/v12020173","volume":"12","author":"Ammour Y.","year":"2020","unstructured":"Ammour Y.; Ryabaya O.; Shchetinina Y.; Prokofeva E.; Gavrilova M.; Khochenkov D.; Vorobyev D.; Faizuloev E.; Shohin I.; Zverev V.V.; Svitich O.; Nasedkina T.; The susceptibility of human melanoma cells to infection with the Leningrad-16 vaccine strain of measles virus. Viruses 2020,12(2),E173","journal-title":"Viruses"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"E1403","DOI":"10.3390\/cancers12061403","volume":"12","author":"Mach N.","year":"2020","unstructured":"Mach N.; Gao J.; Schaffarczyk L.; Janz S.; Ehrke-Schulz E.; Dittmar T.; Ehrhardt A.; Zhang W.; Spectrum-wide exploration of human adenoviruses for breast cancer therapy. Cancers 2020,12(6),E1403","journal-title":"Cancers"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1471-2407-12-99","volume":"12","author":"Geletneky K.","year":"2012","unstructured":"Geletneky K.; Huesing J.; Rommelaere J.; Schlehofer J.R.; Leuchs B.; Dahm M.; Krebs O.; von Knebel Doeberitz M.; Huber B.; Hajda J.; Phase I\/IIa study of intratumoral\/intracerebral or intravenous\/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 2012,12(1),99","journal-title":"BMC Cancer"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-21-1020","volume":"27","author":"Hajda J.","year":"2021","unstructured":"Hajda J.; Leuchs B.; Angelova A.L.; Frehtman V.; Rommelaere J.; Mertens M.; Pilz M.; Kieser M.; Krebs O.; Dahm M.; Huber B.; Engeland C.E.; Mavratzas A.; Hohmann N.; Schreiber J.; J&#xE4;ger D.; Halama N.; Sedlaczek O.; Gaida M.M.; Daniel V.; Springfeld C.; Ungerechts G.; Phase 2 trial of Oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma. Clin Cancer Res 2021,27(20),5546-5556","journal-title":"Clin Cancer Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.15690\/vramn.v67i2.121","volume":"67","author":"Loktev V.B.","year":"2012","unstructured":"Loktev V.B.; Ivan\u2019kina T.Y.; Netesov S.V.; Chumakov P.M.; Oncolytic parvoviruses. New approaches for cancer therapy. Vestnik. Russ Acad Med Sci 2012,67(2),42-47","journal-title":"Russ Acad Med Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3103\/S0891416812010041","volume":"27","author":"Kochneva G.V.","year":"2012","unstructured":"Kochneva G.V.; Sivolobova G.F.; Iudina K.V.; Babkin I.V.; Chumakov P.M.; Netesov S.V.; Oncolytic poxviruses. Mol Gen Mikrobiol Virusol 2012,27(1),8-15","journal-title":"Mol Gen Mikrobiol Virusol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1134\/S0026893312050032","volume":"46","author":"Chumakov P.M.","year":"2012","unstructured":"Chumakov P.M.; Morozova V.V.; Babkin I.V.; Ba&#x12D;kov I.K.; Netesov S.V.; Tikunova N.V.; Oncolytic enteroviruses. Mol Biol 2012,46(5),712-725","journal-title":"Mol Biol"},{"key":"ref=26","first-page":"936","volume":"10","author":"Soboleva A.V.","year":"2018","unstructured":"Soboleva A.V.; Seryak D.A.; Gabdrakhmanova A.F.; Sosnovtseva A.O.; Tkhe L.H.; Kochetkov D.V.; Ilyinskaya G.V.; Lipatova A.V.; Chumakov P.M.; Golbin D.A.; Glioblastoma multiforme stem cells are highly sensitive to some human non-pathogenic enteroviruses. J Pharm Sci Res 2018,10(4),936-939","journal-title":"J Pharm Sci Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12967-016-1002-x","volume":"14","author":"Goncharova E.P.","year":"2016","unstructured":"Goncharova E.P.; Ruzhenkova J.S.; Petrov I.S.; Shchelkunov S.N.; Zenkova M.A.; Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro. J Transl Med 2016,14(1),241","journal-title":"J Transl Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3103\/S0891416820020032","volume":"35","author":"Bauer T.V.","year":"2020","unstructured":"Bauer T.V.; Tregubchak T.V.; Maksyutov A.Z.; Taranov O.S.; Solovieva O.I.; Razumov I.A.; Zavjalov E.L.; Maksyutov R.A.; Gavrilova E.V.; Recombinant vaccinia virus promising for melanoma treatment. Mol Gen Microbiol Virol 2020,35(2),97-104","journal-title":"Mol Gen Microbiol Virol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.3390\/v8010020","volume":"8","author":"Zonov E.","year":"2016","unstructured":"Zonov E.; Kochneva G.; Yunusova A.; Grazhdantseva A.; Richter V.; Ryabchikova E.; Features of the antitumor effect of vaccinia virus lister strain. Viruses 2016,8(1),E20","journal-title":"Viruses"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.24075\/brsmu.2018.032","volume":"3","author":"Sidorenko A.S.","year":"2018","unstructured":"Sidorenko A.S.; Zheltukhin A.O.; Le T.H.; Soboleva A.V.; Lipatova A.V.; Golbin D.A.; Chumakov P.M.; Persistence of oncolytic coxsackie virus A7 in subcutaneous human glioblastoma xenografts in mice in the context of experimental therapy. Bull Russ State Medl. Univ 2018,3(3),42-48","journal-title":"Univ"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.18821\/1028-9984-2017-22-2-158-163","volume":"22","author":"Sosnovtceva A.O.","year":"2017","unstructured":"Sosnovtceva A.O.; Karshieva S.S.; Smirnova G.B.; Borisova Y.A.; Lebedinskaya O.V.; Shubina I.Z.; Treshalina H.M.; Chumakov P.M.; Chekhonin V.P.; Sensitivity of the transplanted human neuroblastoma to oncolytic coxsackie A7 virus. Russian J Oncol 2017,22(3),158-163","journal-title":"Russian J Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.24075\/vrgmu.2018.026","volume":"2","author":"Zheltukhin A.O.","year":"2018","unstructured":"Zheltukhin A.O.; Soboleva A.V.; Sosnovtseva A.O.; Le T.H.; Ilyinskaya G.V.; Kochetkov D.V.; Lipatova A.V.; Chumakov P.M.; Human enteroviruses exhibit selective oncolytic activity in the model of human glioblastoma multiforme xenografts In immunodeficient mice. Bull Russ State Med Univ 2018,2,45-51","journal-title":"Bull Russ State Med Univ"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"16088","DOI":"10.1038\/s41598-021-94573-y","volume":"11","author":"Stepanenko A.A.","year":"2021","unstructured":"Stepanenko A.A.; Sosnovtseva A.O.; Valikhov M.P.; Chekhonin V.P.; A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugation. Sci Rep 2021,11(1),16088","journal-title":"Sci Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.21873\/anticanres.13815","volume":"39","author":"Romanenko M.V.","year":"2019","unstructured":"Romanenko M.V.; Dolgova E.V.; Osipov I.D.; Ritter G.S.; Sizova M.S.; Proskurina A.S.; Efremov Y.R.; Bayborodin S.I.; Potter E.A.; Taranov O.S.; Omigov V.V.; Kochneva G.V.; Grazhdantseva A.A.; Zavyalov E.L.; Razumov I.A.; Netesov S.V.; Bogachev S.S.; Oncolytic effect of adenoviruses serotypes 5 and 6 against U87 glioblastoma cancer stem cells. Anticancer Res 2019,39(11),6073-6086","journal-title":"Anticancer Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1134\/S0026893312040103","volume":"46","author":"Svyatchenko V.A.","year":"2012","unstructured":"Svyatchenko V.A.; Tarasova M.V.; Netesov S.V.; Chumakov P.M.; Oncolytic Adenoviruses in anticancer therapy: Current status and prospects. Mol Biol 2012,46(4),496-507","journal-title":"Mol Biol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.31857\/S0869-5873895475-484","volume":"89","author":"Chumakov P.M.","year":"2019","unstructured":"Chumakov P.M.; Could oncolytic viruses provide a breakthrough in oncology? Her Russ Acad Sci 2019,89(5),475-484","journal-title":"Her Russ Acad Sci"},{"key":"ref=37","author":"Zilber L.A.","year":"1946","unstructured":"Zilber L.A.;  Viral theory of the origin of malignant tumors 1946","journal-title":"Viral theory of the origin of malignant tumors"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"17937","DOI":"10.1073\/pnas.1920988117","volume":"117","author":"Lidsky P.V.","year":"2020","unstructured":"Lidsky P.V.; Andino R.; Epidemics as an adaptive driving force determining lifespan setpoints. Proc Natl Acad Sci USA 2020,117(30),17937-17948","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=39","first-page":"191","volume":"36","author":"Voroshilova M.K.","year":"1989","unstructured":"Voroshilova M.K.; Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol 1989,36,191-202","journal-title":"Prog Med Virol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"E484","DOI":"10.3390\/biomedicines8110484","volume":"8","author":"Chouljenko D.V.","year":"2020","unstructured":"Chouljenko D.V.; Ding J.; Lee I.F.; Murad Y.M.; Bu X.; Liu G.; Delwar Z.; Sun Y.; Yu S.; Samudio I.; Zhao R.; Jia W.W.; Induction of durable antitumor response by a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. Biomedicines 2020,8(11),E484","journal-title":"Biomedicines"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/s41467-021-22088-1","volume":"12","author":"Brown M.C.","year":"2021","unstructured":"Brown M.C.; Mosaheb M.M.; Mohme M.; McKay Z.P.; Holl E.K.; Kastan J.P.; Yang Y.; Beasley G.M.; Hwang E.S.; Ashley D.M.; Bigner D.D.; Nair S.K.; Gromeier M.; Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. Nat Commun 2021,12(1),1858","journal-title":"Nat Commun"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e947872","DOI":"10.4161\/21624011.2014.947872","volume":"3","author":"Jiang H.","year":"2014","unstructured":"Jiang H.; Fueyo J.; Healing after death: Antitumor immunity induced by oncolytic adenoviral therapy. OncoImmunology 2014,3(7),e947872","journal-title":"OncoImmunology"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1071059","volume":"296","author":"Matzinger P.","year":"2002","unstructured":"Matzinger P.; The danger model: A renewed sense of self. Science 2002,296(5566),301-305","journal-title":"Science"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"e2008","DOI":"10.1002\/rmv.2008","volume":"28","author":"Matveeva O.V.","year":"2018","unstructured":"Matveeva O.V.; Chumakov P.M.; Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses. Rev Med Virol 2018,28(6),e2008","journal-title":"Rev Med Virol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"634","DOI":"10.31857\/S0026898420040102","volume":"54","author":"Le T.H.","year":"2020","unstructured":"Le T.H.; Lipatova A.V.; Volskaya M.A.; Tikhonova O.A.; Chumakov P.M.; The State of the jak\/stat pathway affects the sensitivity of tumor cells to oncolytic enteroviruses. Mol Biol 2020,54(4),634-642","journal-title":"Mol Biol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.3390\/cancers13143482","volume":"13","author":"Kamynina M.","year":"2021","unstructured":"Kamynina M.; Tskhovrebova S.; Fares J.; Timashev P.; Laevskaya A.; Ulasov I.; Oncolytic virus-induced autophagy in glioblastoma. Cancers 2021,13(14),3482","journal-title":"Cancers"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1038\/s41388-018-0395-9","volume":"37","author":"Kaverina N.V.","year":"2018","unstructured":"Kaverina N.V.; Kadagidze Z.G.; Borovjagin A.V.; Karseladze A.I.; Kim C.K.; Lesniak M.S.; Miska J.; Zhang P.; Baryshnikova M.A.; Xiao T.; Ornelles D.; Cobbs C.; Khramtsov A.; Ulasov I.V.; Tamoxifen overrides autophagy inhibition in beclin-1-deficient glioma cells and their resistance to adenovirus-mediated oncolysis via upregulation of PUMA and BAX. Oncogene 2018,37(46),6069-6082","journal-title":"Oncogene"},{"key":"ref=48","first-page":"9","volume":"4","author":"Kallinikova V.D.","year":"2006","unstructured":"Kallinikova V.D.; Borisova E.N.; Pakhorukova L.V.; Ogloblina T.A.; Batmonkh T.; Kravtsov E.G.; Karpenko L.P.; Dalin M.V.; Immunization against Trypanosoma cruzi and tumor growth in mice. Med Parazitol 2006,4,9-12","journal-title":"Med Parazitol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3390\/v13040552","volume":"13","author":"Yurchenko K.S.","year":"2021","unstructured":"Yurchenko K.S.; Glushchenko A.V.; Gulyaeva M.A.; Bi Y.; Chen J.; Shi W.; Adamenko L.S.; Shestopalov A.M.; Intratumoral virotherapy with wild-type newcastle disease virus in carcinoma Krebs-2 cancer model. Viruses 2021,13(4),552","journal-title":"Viruses"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1134\/S002689331803010X","volume":"52","author":"Matveeva O.V.","year":"2018","unstructured":"Matveeva O.V.; Kochneva G.V.; Zainutdinov S.S.; Ilyinskaya G.V.; Chumakov P.M.; Oncolytic paramyxoviruses: Mechanism of action, preclinical and clinical studies. Mol Biol 2018,52(3),360-379","journal-title":"Mol Biol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"15011","DOI":"10.1038\/mto.2015.11","volume":"2","author":"Matveeva O.V.","year":"2015","unstructured":"Matveeva O.V.; Guo Z.S.; Shabalina S.A.; Chumakov P.M.; Oncolysis by paramyxoviruses: Multiple mechanisms contribute to therapeutic efficiency. Mol Ther Oncolytics 2015,2,15011","journal-title":"Mol Ther Oncolytics"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.32607\/20758251-2015-7-2-6-16","volume":"7","author":"Matveeva O.V.","year":"2015","unstructured":"Matveeva O.V.; Kochneva G.V.; Netesov S.V.; Onikienko S.B.; Chumakov P.M.; Mechanisms of oncolysis by paramyxovirus sendai. Acta Nat 2015,7(2),6-16","journal-title":"Acta Nat"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3389\/fvets.2018.00116","volume":"5","author":"Ilyinskaya G.V.","year":"2018","unstructured":"Ilyinskaya G.V.; Mukhina E.V.; Soboleva A.V.; Matveeva O.V.; Chumakov P.M.; Oncolytic sendai virus therapy of canine mast cell tumors: (A pilot study). Front Vet Sci 2018,5,116","journal-title":"Front Vet Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s10517-016-3520-1","volume":"161","author":"Sosnovtseva A.O.","year":"2016","unstructured":"Sosnovtseva A.O.; Lipatova A.V.; Grinenko N.F.; Baklaushev V.P.; Chumakov P.M.; Chekhonin V.P.; Sensitivity of C6 glioma cells carrying the human poliovirus receptor to oncolytic polioviruses. Bull Exp Biol Med 2016,161(6),821-825","journal-title":"Bull Exp Biol Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10517-019-04472-6","volume":"167","author":"Sosnovtseva A.O.","year":"2019","unstructured":"Sosnovtseva A.O.; Zheltukhin A.O.; Lipatova A.V.; Chumakov P.M.; Chekhonin V.P.; Oncolytic activity of the vaccine strain of type 3 poliovirus on the model of rat glioma C6 cells. Bull Exp Biol Med 2019,167(1),111-115","journal-title":"Bull Exp Biol Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1084\/jem.20171093","volume":"214","author":"Zhu Z.","year":"2017","unstructured":"Zhu Z.; Gorman M.J.; McKenzie L.D.; Chai J.N.; Hubert C.G.; Prager B.C.; Fernandez E.; Richner J.M.; Zhang R.; Shan C.; Tycksen E.; Wang X.; Shi P.Y.; Diamond M.S.; Rich J.N.; Chheda M.G.; Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med 2017,214(10),2843-2857","journal-title":"J Exp Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.18699\/VJ18.448","volume":"22","author":"Svyatchenko V.A.","year":"2018","unstructured":"Svyatchenko V.A.; Razumov I.A.; Protopopova E.V.; Demina A.V.; Solovieva O.I.; Zavjalov E.L.; Loktev V.B.; Zika virus has an oncolytic activity against human glioblastoma U87 cells. Vavilovskii Zhurnal Genet Selektsii 2018,22(8),1040-1045","journal-title":"Vavilovskii Zhurnal Genet Selektsii"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cytogfr.2020.07.015","volume":"56","author":"Tassone E.","year":"2020","unstructured":"Tassone E.; Muscolini M.; van Montfoort N.; Hiscott J.; Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment? Cytokine Growth Factor Rev 2020,56,141-148","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"E492","DOI":"10.3390\/cancers10120492","volume":"10","author":"Stepanenko A.A.","year":"2018","unstructured":"Stepanenko A.A.; Chekhonin V.P.; Recent Advances in Oncolytic Virotherapy and Immunotherapy for glioblastoma: A glimmer of hope in the search for an effective therapy? Cancers 2018,10(12),E492","journal-title":"Cancers"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"376","DOI":"10.18097\/PBMC20166204376","volume":"62","author":"Sosnovtceva A.O.","year":"2016","unstructured":"Sosnovtceva A.O.; Grinenko N.F.; Lipatova A.V.; Chumakov P.M.; Chekhonin V.P.; Oncolytic viruses for therapy of malignant glioma. Biomed Khim 2016,62,376-390","journal-title":"Biomed Khim"},{"key":"ref=61","first-page":"6","volume":"2","author":"Baklaushev V.P.","year":"2015","unstructured":"Baklaushev V.P.; Goryainov S.A.; Potapov A.A.; Pavlova G.V.; Chehonin V.P.; Oncolytic Viruses In High-Grade Gliomas Treatment. J Clin Pract 2015,2,6-59","journal-title":"J Clin Pract"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/OV.S176523","volume":"8","author":"Zainutdinov S.S.","year":"2019","unstructured":"Zainutdinov S.S.; Kochneva G.V.; Netesov S.V.; Chumakov P.M.; Matveeva O.V.; Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes. Oncolytic Virother 2019,8,9-26","journal-title":"Oncolytic Virother"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1007\/s00705-017-3492-0","volume":"162","author":"Svyatchenko V.A.","year":"2017","unstructured":"Svyatchenko V.A.; Ternovoy V.A.; Kiselev N.N.; Demina A.V.; Loktev V.B.; Netesov S.V.; Chumakov P.M.; Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines. Arch Virol 2017,162(11),3355-3362","journal-title":"Arch Virol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"66","DOI":"10.32607\/20758251-2019-11-1-66-73","volume":"11","author":"Yurchenko K.S.","year":"2019","unstructured":"Yurchenko K.S.; Jing Y.; Shestopalov A.M.; Adaptation of the new castle disease virus to cell cultures for enhancing its oncolytic properties. Acta Nat 2019,11(1),66-73","journal-title":"Acta Nat"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3103\/S0891416817040115","volume":"32","author":"Zainutdinov S.S.","year":"2017","unstructured":"Zainutdinov S.S.; Sivolobova G.F.; Grazhdantseva A.A.; Kochneva G.V.; Changes in oncolytic activity of Sendai virus during adaptation to cell cultures. Mol Gen Microbiol Virol 2017,32(4),212-217","journal-title":"Mol Gen Microbiol Virol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"40","DOI":"10.24075\/vrgmu.2018.025","volume":"2","author":"Soboleva A.V.","year":"2018","unstructured":"Soboleva A.V.; Lipatova A.V.; Kochetkov D.V.; Chumakov P.M.; Changes in the sensitivity of human glioblastoma cells to oncolytic enteroviruses induced by passaging. Bull Russ State Med Univ 2018,2,40-44","journal-title":"Bull Russ State Med Univ"},{"year":"2001","author":"Kachko A.V.","key":"ref=67","unstructured":"Kachko A.V.; Ternovoj V.A.; Kiselev N.N.; Sorokin A.V.; Svjatchenko V.A.; Netesov S.V.; Kiselev S.L.; Recombinant plasmid DNA PAD5-F carrying of adenovirus type 5 genome fragment with deletion in gene E1B-55K and strain of mutant adenovirus Ade 12 exhibiting selective antitumor activity. 2001"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.gendis.2014.09.009","volume":"1","author":"Ulasov I.V.","year":"2014","unstructured":"Ulasov I.V.; Borovjagin A.V.; Schroeder B.A.; Baryshnikov A.Y.; Oncolytic adenoviruses: A thorny path to glioma cure. Genes Dis 2014,1(2),214-226","journal-title":"Genes Dis"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1134\/S0003683816070036","volume":"52","author":"Grazhdantseva A.A.","year":"2016","unstructured":"Grazhdantseva A.A.; Sivolobova G.F.; Tkacheva A.V.; Gileva I.P.; Kochneva G.V.; Kuligina E.V.; Rikhter V.A.; Highly effective production of biologically active, secreted, human granulocyte-macrophage colony-stimulating factor by recombinant vaccinia virus. Appl Biochem Microbiol 2016,52(7),685-691","journal-title":"Appl Biochem Microbiol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S1470-2045(13)70274-2","volume":"14","author":"Westphal M.","year":"2013","unstructured":"Westphal M.; Yl&#xE4;-Herttuala S.; Martin J.; Warnke P.; Menei P.; Eckland D.; Kinley J.; Kay R.; Ram Z.; Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomised, open-label, phase 3 trial. Lancet Oncol 2013,14(9),823-833","journal-title":"Lancet Oncol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1472-6750-8-49","volume":"8","author":"Liu B.","year":"2008","unstructured":"Liu B.; Paton J.F.; Kasparov S.; Viral vectors based on bidirectional cell-specific mammalian promoters and transcriptional amplification strategy for use in vitro and in vivo. BMC Biotechnol 2008,8(1),49","journal-title":"BMC Biotechnol"},{"key":"ref=72","first-page":"11","volume":"9","author":"Kochneva G.V.","year":"2017","unstructured":"Kochneva G.V.; Tkacheva A.V.; Sivolobova G.F.; Grazhdantseva A.A.; Yunusova A.Yu.; Ryabchikova E.I.; Kuligina E.V.; Koval O.A.; Rikhter V.A.; Antitumor potential of recombinant vaccinia virus strain, which produces a secreted chimera protein, composed of human Gm-Csf and oncotoxic peptide lactaptin. Russian J Biopharmaceut 2017,9,11-21","journal-title":"Russian J Biopharmaceut"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1021\/bi7023207","volume":"47","author":"Patel S.","year":"2008","unstructured":"Patel S.; Bui T.T.T.; Drake A.F.; Fraternali F.; Nikolova P.V.; The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding. Biochemistry 2008,47(10),3235-3244","journal-title":"Biochemistry"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.2174\/138920112800958922","volume":"13","author":"Breitbach C.J.","year":"2012","unstructured":"Breitbach C.J.; Thorne S.H.; Bell J.C.; Kirn D.H.; Targeted and armed oncolytic poxviruses for cancer: The lead example of JX-594. Curr Pharm Biotechnol 2012,13(9),1768-1772","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1134\/S0026893313050075","volume":"47","author":"Kochneva G.V.","year":"2013","unstructured":"Kochneva G.V.; Babkina I.N.; Lupan T.A.; Grazhdantseva A.A.; Yudin P.V.; Sivolobova G.F.; Shvalov A.N.; Popov E.G.; Babkin I.V.; Netesov S.V.; Chumakov P.M.; Apoptin enhances the oncolytic activity of vaccinia virus in vitro. Mol Biol 2013,47(5),733-742","journal-title":"Mol Biol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3103\/S089141681604008X","volume":"31","author":"Zonov E.V.","year":"2016","unstructured":"Zonov E.V.; Tupitsyna A.V.; Ryabchikova E.I.; Kochneva G.V.; The in vivo antitumor effect of the apoptin-producing recombinant vaccinia virus strain is associated with blockage of mitotic division of cancer cells. Mol Gen Microbiol Virol 2016,31(4),233-239","journal-title":"Mol Gen Microbiol Virol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"11269","DOI":"10.18632\/oncotarget.2579","volume":"5","author":"Kochneva G.","year":"2014","unstructured":"Kochneva G.; Zonov E.; Grazhdantseva A.; Yunusova A.; Sibolobova G.; Popov E.; Taranov O.; Netesov S.; Chumakov P.; Ryabchikova E.; Apoptin enhances the oncolytic properties of vaccinia virus and modifies mechanisms of tumor regression. Oncotarget 2014,5(22),11269-11282","journal-title":"Oncotarget"},{"key":"ref=78","first-page":"100","volume":"3","author":"Ternovoy V.A.","year":"2013","unstructured":"Ternovoy V.A.; Svyatchenko V.A.; Tarasova M.V.; Kiselev N.N.; Chub E.V.; Mikryukova T.P.; Protopopova E.V.; Loktev V.B.; Chumakov P.M.; Netesov S.V.; The construction of recombinant adenoviruses expressing apoptin. Tomsk State J Biol 2013,3,100-110","journal-title":"Tomsk State J Biol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3103\/S0891416819020101","volume":"34","author":"Tkacheva A.V.","year":"2019","unstructured":"Tkacheva A.V.; Sivolobova G.F.; Grazhdantseva A.A.; Loktev V.B.; Kochneva G.V.; Shevelev O.B.; Razumov I.A.; Zavjalov E.L.; Targeted therapy of human glioblastoma combining the oncolytic properties of parvovirus H-1 and attenuated strains of the vaccinia virus. Mol Gen Microbiol Virol 2019,34(2),140-147","journal-title":"Mol Gen Microbiol Virol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"74171","DOI":"10.18632\/oncotarget.12367","volume":"7","author":"Kochneva G.","year":"2016","unstructured":"Kochneva G.; Sivolobova G.; Tkacheva A.; Grazhdantseva A.; Troitskaya O.; Nushtaeva A.; Tkachenko A.; Kuligina E.; Richter V.; Koval O.; Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy. Oncotarget 2016,7(45),74171-74188","journal-title":"Oncotarget"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.virusres.2018.08.012","volume":"257","author":"Stepanenko A.A.","year":"2018","unstructured":"Stepanenko A.A.; Chekhonin V.P.; Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX. Virus Res 2018,257,40-51","journal-title":"Virus Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.gene.2018.08.069","volume":"679","author":"Stepanenko A.A.","year":"2018","unstructured":"Stepanenko A.A.; Chekhonin V.P.; A compendium of adenovirus genetic modifications for enhanced replication, oncolysis, and tumor immunosurveillance in cancer therapy. Gene 2018,679,11-18","journal-title":"Gene"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.gt.3302146","volume":"11","author":"Logunov D.Y.","year":"2004","unstructured":"Logunov D.Y.; Ilyinskaya G.V.; Cherenova L.V.; Verhovskaya L.V.; Shmarov M.M.; Chumakov P.M.; Kopnin B.P.; Naroditsky B.S.; Restoration of p53 tumor-suppressor activity in human tumor cells in vitro and in their xenografts in vivo by recombinant avian adenovirus CELO-p53. Gene Ther 2004,11(1),79-84","journal-title":"Gene Ther"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.cgt.7700539","volume":"9","author":"Reid T.","year":"2002","unstructured":"Reid T.; Warren R.; Kirn D.; Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther 2002,9(12),979-986","journal-title":"Cancer Gene Ther"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12985-021-01630-z","volume":"18","author":"Xie R.","year":"2021","unstructured":"Xie R.; Bi X.; Shang B.; Zhou A.; Shi H.; Shou J.; Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: A network meta-analysis. Virol J 2021,18(1),158","journal-title":"Virol J"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/sj.mt.6300215","volume":"15","author":"Breitbach C.J.","year":"2007","unstructured":"Breitbach C.J.; Paterson J.M.; Lemay C.G.; Falls T.J.; McGuire A.; Parato K.A.; Stojdl D.F.; Daneshmand M.; Speth K.; Kirn D.; McCart J.A.; Atkins H.; Bell J.C.; Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007,15(9),1686-1693","journal-title":"Mol Ther"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fonc.2020.00475","volume":"10","author":"Li L.","year":"2020","unstructured":"Li L.; Liu S.; Han D.; Tang B.; Ma J.; Delivery and biosafety of oncolytic virotherapy. Front Oncol 2020,10,475","journal-title":"Front Oncol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"e002203","DOI":"10.1136\/jitc-2020-002203","volume":"9","author":"Beasley G.M.","year":"2021","unstructured":"Beasley G.M.; Nair S.K.; Farrow N.E.; Landa K.; Selim M.A.; Wiggs C.A.; Jung S-H.; Bigner D.D.; True Kelly A.; Gromeier M.; Salama A.K.; Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. J Immunother Cancer 2021,9(4),e002203","journal-title":"J Immunother Cancer"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/CAD.0b013e32832a2df9","volume":"20","author":"Tian G.","year":"2009","unstructured":"Tian G.; Liu J.; Zhou J.S.R.; Chen W.; Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A pilot phase II trial. Anticancer Drugs 2009,20(5),389-395","journal-title":"Anticancer Drugs"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"e2100194","DOI":"10.1002\/bies.202100194","volume":"43","author":"Tyshkovskiy A.","year":"2021","unstructured":"Tyshkovskiy A.; Panchin A.Y.; There is still no evidence of SARS-CoV-2 laboratory origin: Response to segreto and deigin. Bioessays 2021,43(12),e2100194","journal-title":"Bioessays"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"111785","DOI":"10.1016\/j.envres.2021.111785","volume":"200","author":"Domingo J.L.","year":"2021","unstructured":"Domingo J.L.; What we know and what we need to know about the origin of SARS-CoV-2. Environ Res 2021,200,111785","journal-title":"Environ Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"E94","DOI":"10.3390\/biomedicines6040094","volume":"6","author":"Chulpanova D.S.","year":"2018","unstructured":"Chulpanova D.S.; Solovyeva V.V.; Kitaeva K.V.; Dunham S.P.; Khaiboullina S.F.; Rizvanov A.A.; Recombinant viruses for cancer therapy. Biomedicines 2018,6(4),E94","journal-title":"Biomedicines"},{"key":"ref=93","volume":"9","author":"Berzhitskaya D.","year":"2019","unstructured":"Berzhitskaya D.; Chumakov P.; Dendritic cells as carriers of oncolytic viruses. FEBS Open Bio 2019,9(S1)","journal-title":"FEBS Open Bio"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.omto.2021.03.013","volume":"21","author":"Podshivalova E.S.","year":"2021","unstructured":"Podshivalova E.S.; Semkina A.S.; Kravchenko D.S.; Frolova E.I.; Chumakov S.P.; Efficient delivery of oncolytic enterovirus by carrier cell line NK-92. Mol Ther Oncolytics 2021,21,110-118","journal-title":"Mol Ther Oncolytics"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1634\/stemcells.2007-0758","volume":"26","author":"Sonabend A.M.","year":"2008","unstructured":"Sonabend A.M.; Ulasov I.V.; Tyler M.A.; Rivera A.A.; Mathis J.M.; Lesniak M.S.; Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008,26(3),831-841","journal-title":"Stem Cells"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1039\/C9BM00926D","volume":"8","author":"Muslimov A.R.","year":"2020","unstructured":"Muslimov A.R.; Timin A.S.; Bichaykina V.R.; Peltek O.O.; Karpov T.E.; Dubavik A.; Nomin&#xE9; A.; Ghanbaja J.; Sukhorukov G.B.; Zyuzin M.V.; Biomimetic drug delivery platforms based on mesenchymal stem cells impregnated with light-responsive submicron sized carriers. Biomater Sci 2020,8(4),1137-1147","journal-title":"Biomater Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"Logunov D.Y.","year":"2020","unstructured":"Logunov D.Y.; Dolzhikova I.V.; Zubkova O.V.; Tukhvatullin A.I.; Shcheblyakov D.V.; Dzharullaeva A.S.; Grousova D.M.; Erokhova A.S.; Kovyrshina A.V.; Botikov A.G.; Izhaeva F.M.; Popova O.; Ozharovskaya T.A.; Esmagambetov I.B.; Favorskaya I.A.; Zrelkin D.I.; Voronina D.V.; Shcherbinin D.N.; Semikhin A.S.; Simakova Y.V.; Tokarskaya E.A.; Lubenets N.L.; Egorova D.A.; Shmarov M.M.; Nikitenko N.A.; Morozova L.F.; Smolyarchuk E.A.; Kryukov E.V.; Babira V.F.; Borisevich S.V.; Naroditsky B.S.; Gintsburg A.L.; Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Russia. Lancet 2020,396(10255),887-897","journal-title":"Lancet"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"150017","DOI":"10.1038\/mto.2015.17","volume":"2","author":"Matveeva O.V.","year":"2015","unstructured":"Matveeva O.V.; Guo Z.S.; Senin V.M.; Senina A.V.; Shabalina S.A.; Chumakov P.M.; Oncolysis by paramyxoviruses: Preclinical and clinical studies. Mol Ther Oncolytics 2015,2,150017","journal-title":"Mol Ther Oncolytics"},{"key":"ref=99","first-page":"83","volume":"1","author":"Vdovochenko G.V.","year":"2006","unstructured":"Vdovochenko G.V.; Radaeva I.F.; Sergeev A.A.; Kolokol\u2019tsova T.d.; Nechaeva E.A.; Il\u2019ina T.v.; Petrishchenko V.A.; Ternovoy V.A.; Sviatchenko V.A.; Sergeev A.N.; Development of banks of a 203-cell continuous culture for manufacturing the anti-tumor therapeutic preparation cancerolysin. Biotechnol Russ 2006,1,83-89","journal-title":"Biotechnol Russ"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.3390\/ijms21207505","volume":"21","author":"Cook M.","year":"2020","unstructured":"Cook M.; Chauhan A.; Clinical application of oncolytic viruses: A systematic review. Int J Mol Sci 2020,21(20),7505","journal-title":"Int J Mol Sci"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cytogfr.2020.06.010","volume":"56","author":"Kemp V.","year":"2020","unstructured":"Kemp V.; Lamfers M.L.M.; van der Pluijm G.; van den Hoogen B.G.; Hoeben R.C.; Developing oncolytic viruses for clinical use: A consortium approach. Cytokine Growth Factor Rev 2020,56,133-140","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.virol.2015.08.003","volume":"485","author":"Cataldi M.","year":"2015","unstructured":"Cataldi M.; Shah N.R.; Felt S.A.; Grdzelishvili V.Z.; Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1. Virology 2015,485,340-354","journal-title":"Virology"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"688755","DOI":"10.3389\/fonc.2021.688755","volume":"11","author":"Vandeborne L.","year":"2021","unstructured":"Vandeborne L.; Pantziarka P.; Van Nuffel A.M.T.; Bouche G.; repurposing infectious diseases vaccines against cancer. Front Oncol 2021,11,688755","journal-title":"Front Oncol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"e01860","DOI":"10.1128\/mBio.01860-17","volume":"8","author":"Kasaraneni N.","year":"2017","unstructured":"Kasaraneni N.; Chamoun-Emanuelli A.M.; Wright G.; Chen Z.; Retargeting lentiviruses via SpyCatcher-SpyTag chemistry for gene delivery into specific cell types. MBio 2017,8(6),e01860-17","journal-title":"MBio"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"201909653","DOI":"10.1073\/pnas.1909653116","volume":"116","author":"Keeble A.H.","year":"2019","unstructured":"Keeble A.H.; Turkki P.; Stokes S.; Khairil Anuar I.N.A.; Rahikainen R.; Hyt&#xF6;nen V.P.; Howarth M.; Approaching infinite affinity through engineering of peptide-protein interaction. Proc Natl Acad Sci USA 2019,116(52),201909653","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00216-018-1519-3","volume":"411","author":"Huang L.L.","year":"2019","unstructured":"Huang L.L.; Li X.; Liu K.; Zou B.; Xie H.Y.; Engineering oncolytic vaccinia virus with functional peptides through mild and universal strategy. Anal Bioanal Chem 2019,411(4),925-933","journal-title":"Anal Bioanal Chem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"E3055","DOI":"10.3390\/polym12123055","volume":"12","author":"Thangudu S.","year":"2020","unstructured":"Thangudu S.; Cheng F.Y.; Su C.H.; Advancements in the blood-brain barrier penetrating nanoplatforms for brain related disease diagnostics and therapeutic applications. Polymers, (Basel) 2020,12(12),E3055","journal-title":"Polymers, (Basel)"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"E5294","DOI":"10.3390\/molecules25225294","volume":"25","author":"Zorkina Y.","year":"2020","unstructured":"Zorkina Y.; Abramova O.; Ushakova V.; Morozova A.; Zubkov E.; Valikhov M.; Melnikov P.; Majouga A.; Chekhonin V.; Nano carrier drug delivery systems for the treatment of neuropsychiatric disorders: Advantages and limitations. Molecules 2020,25(22),E5294","journal-title":"Molecules"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.2174\/1568026620666201113140258","volume":"21","author":"Ganjeifar B.","year":"2020","unstructured":"Ganjeifar B.; Morshed S.F.; Targeted drug delivery in brain tumors- nanochemistry applications and advances. Curr Top Med Chem 2020,21(14),1202-1223","journal-title":"Curr Top Med Chem"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"E1171","DOI":"10.3390\/pharmaceutics12121171","volume":"12","author":"Klyachko N.L.","year":"2020","unstructured":"Klyachko N.L.; Arzt C.J.; Li S.M.; Gololobova O.A.; Batrakova E.V.; Extracellular vesicle-based therapeutics: Preclinical and clinical investigations. Pharmaceutics 2020,12(12),E1171","journal-title":"Pharmaceutics"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1080\/1061186X.2021.1912053","volume":"29","author":"Han M.","year":"2021","unstructured":"Han M.; Xing H.; Chen L.; Cui M.; Zhang Y.; Qi L.; Jin M.; Yang Y.; Gao C.; Gao Z.; Xing X.; Huang W.; Efficient antiglioblastoma therapy in mice through doxorubicin-loaded nanomicelles modified using a novel brain-targeted RVG-15 peptide. J Drug Target 2021,29(9),1016-1028","journal-title":"J Drug Target"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omto.2021.03.011","volume":"21","author":"Hill C.","year":"2021","unstructured":"Hill C.; Grundy M.; Bau L.; Wallington S.; Balkaran J.; Ramos V.; Fisher K.; Seymour L.; Coussios C.; Carlisle R.; Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus. Mol Ther Oncolytics 2021,21,47-61","journal-title":"Mol Ther Oncolytics"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2217\/nnm-2016-0060","volume":"11","author":"Kasala D.","year":"2016","unstructured":"Kasala D.; Yoon A.R.; Hong J.; Kim S.W.; Yun C-O.; Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy. Nanomedicine 2016,11(13),1689-1713","journal-title":"Nanomedicine"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","volume":"81","author":"Alemany R.","year":"2000","unstructured":"Alemany R.; Suzuki K.; Curiel D.T.; Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000,81(Pt 11),2605-2609","journal-title":"J Gen Virol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"11341","DOI":"10.1021\/acsnano.1c00687","volume":"15","author":"Zelepukin I.V.","year":"2021","unstructured":"Zelepukin I.V.; Yaremenko A.V.; Ivanov I.N.; Yuryev M.V.; Cherkasov V.R.; Deyev S.M.; Nikitin P.I.; Nikitin M.P.; Long-term fate of magnetic particles in mice: A comprehensive study. ACS Nano 2021,15(7),11341-11357","journal-title":"ACS Nano"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3390\/pharmaceutics13050750","volume":"13","author":"Korneyenkov M.A.","year":"2021","unstructured":"Korneyenkov M.A.; Zamyatnin A.A.; Next step in gene delivery: Modern approaches and further perspectives of AAV tropism modification. Pharmaceutics 2021,13(5),750","journal-title":"Pharmaceutics"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1128\/JVI.01896-07","volume":"82","author":"Belousova N.","year":"2008","unstructured":"Belousova N.; Mikheeva G.; Gelovani J.; Krasnykh V.; Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. J Virol 2008,82(2),630-637","journal-title":"J Virol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","volume":"22","author":"Fares J.","year":"2021","unstructured":"Fares J.; Ahmed A.U.; Ulasov I.V.; Sonabend A.M.; Miska J.; Lee-Chang C.; Balyasnikova I.V.; Chandler J.P.; Portnow J.; Tate M.C.; Kumthekar P.; Lukas R.V.; Grimm S.A.; Adams A.K.; H&#xE9;bert C.D.; Strong T.V.; Amidei C.; Arrieta V.A.; Zannikou M.; Horbinski C.; Zhang H.; Burdett K.B.; Curiel D.T.; Sachdev S.; Aboody K.S.; Stupp R.; Lesniak M.S.; Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: A first-in-human, phase 1, dose-escalation trial. Lancet Oncol 2021,22(8),1103-1114","journal-title":"Lancet Oncol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"e48064","DOI":"10.1371\/journal.pone.0048064","volume":"7","author":"van den Wollenberg D.J.M.","year":"2012","unstructured":"van den Wollenberg D.J.M.; Dautzenberg I.J.C.; van den Hengel S.K.; Cramer S.J.; de Groot R.J.; Hoeben R.C.; Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A. PLoS One 2012,7(10),e48064","journal-title":"PLoS One"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/mt.2010.79","volume":"18","author":"Guedan S.","year":"2010","unstructured":"Guedan S.; Rojas J.J.; Gros A.; Mercade E.; Cascallo M.; Alemany R.; Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010,18(7),1275-1283","journal-title":"Mol Ther"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1002\/1878-0261.12787","volume":"14","author":"Xia Y.","year":"2020","unstructured":"Xia Y.; He J.; Zhang H.; Wang H.; Tetz G.; Maguire C.A.; Wang Y.; Onuma A.; Genkin D.; Tetz V.; Stepanov A.; Terekhov S.; Ukrainskaya V.; Huang H.; Tsung A.; AAV-mediated gene transfer of DNase I in the liver of mice with colorectal cancer reduces liver metastasis and restores local innate and adaptive immune response. Mol Oncol 2020,14(11),2920-2935","journal-title":"Mol Oncol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","volume":"6","author":"Cloughesy T.F.","year":"2020","unstructured":"Cloughesy T.F.; Petrecca K.; Walbert T.; Butowski N.; Salacz M.; Perry J.; Damek D.; Bota D.; Bettegowda C.; Zhu J.J.; Iwamoto F.; Placantonakis D.; Kim L.; Elder B.; Kaptain G.; Cachia D.; Moshel Y.; Brem S.; Piccioni D.; Landolfi J.; Chen C.C.; Gruber H.; Rao A.R.; Hogan D.; Accomando W.; Ostertag D.; Montellano T.T.; Kheoh T.; Kabbinavar F.; Vogelbaum M.A.; Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: A randomized clinical trial. JAMA Oncol 2020,6(12),1939-1946","journal-title":"JAMA Oncol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"9376","DOI":"10.3390\/ijms22179376","volume":"22","author":"Alekseenko I.","year":"2021","unstructured":"Alekseenko I.; Kuzmich A.; Kondratyeva L.; Kondratieva S.; Pleshkan V.; Sverdlov E.; Step-by-step immune activation for suicide gene therapy reinforcement. Int J Mol Sci 2021,22(17),9376","journal-title":"Int J Mol Sci"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"3620510","DOI":"10.1155\/2017\/3620510","volume":"2017","author":"Koval O.","year":"2017","unstructured":"Koval O.; Kochneva G.; Tkachenko A.; Troitskaya O.; Sivolobova G.; Grazhdantseva A.; Nushtaeva A.; Kuligina E.; Richter V.; Recombinant vaccinia viruses coding transgenes of apoptosis-inducing proteins enhance apoptosis but not immunogenicity of infected tumor cells. BioMed Res Int 2017,2017,3620510","journal-title":"BioMed Res Int"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3390\/life11101084","volume":"11","author":"Vasileva N.","year":"2021","unstructured":"Vasileva N.; Ageenko A.; Dmitrieva M.; Nushtaeva A.; Mishinov S.; Kochneva G.; Richter V.; Kuligina E.; Double recombinant vaccinia virus: A candidate drug against human glioblastoma. Life 2021,11(10),1084","journal-title":"Life"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.omto.2021.12.013","volume":"24","author":"Stepanenko A.A.","year":"2021","unstructured":"Stepanenko A.A.; Sosnovtseva A.O.; Valikhov M.P.; Chernysheva A.A.; Cherepanov S.A.; Yusubalieva G.M.; Ruzsics Z.; Lipatova A.V.; Chekhonin V.P.; Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5\/35 and Ad5\/3 over Ad5-delta-24-RGD in primary glioma cultures. Mol Ther Oncolytics 2021,24,230-248","journal-title":"Mol Ther Oncolytics"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3390\/pharmaceutics13101641","volume":"13","author":"Romanenko M.","year":"2021","unstructured":"Romanenko M.; Osipov I.; Netesov S.V.; Davydova J.; Adenovirus type 6: Subtle structural distinctions from adenovirus type 5 result in essential differences in properties and perspectives for gene therapy. Pharmaceutics 2021,13(10),1641","journal-title":"Pharmaceutics"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3390\/v13071271","volume":"13","author":"Malogolovkin A.","year":"2021","unstructured":"Malogolovkin A.; Gasanov N.; Egorov A.; Weener M.; Ivanov R.; Karabelsky A.; Combinatorial approaches for cancer treatment using oncolytic viruses: projecting the perspectives through clinical trials outcomes. Viruses 2021,13(7),1271","journal-title":"Viruses"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.3390\/cancers13215268","volume":"13","author":"Lipatova A.V.","year":"2021","unstructured":"Lipatova A.V.; Soboleva A.V.; Gorshkov V.A.; Bubis J.A.; Solovyeva E.M.; Krasnov G.S.; Kochetkov D.V.; Vorobyev P.O.; Ilina I.Y.; Moshkovskii S.A.; Kjeldsen F.; Gorshkov M.V.; Chumakov P.M.; Tarasova I.A.; Multi-Omics Analysis of Glioblastoma Cells\u2019 Sensitivity to Oncolytic Viruses. Cancers 2021,13(21),5268","journal-title":"Cancers"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201023666220516121813","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204836\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201023666220516121813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T13:01:14Z","timestamp":1677848474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204836\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":129,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201023666220516121813","relation":{},"ISSN":["1389-2010"],"issn-type":[{"type":"print","value":"1389-2010"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}